Targeted cancer drugs finally living up to the hype

Targeted cancer drugs finally living up to the hype
Big pharmaceutical companies are backing so-called antibody-drug conjugates. (Image: Bloomberg)
Bloomberg
By Lisa JarvisCancer drugs that work like heat-seeking missiles to deliver chemicals directly to tumours are having a bit of a moment. Pharmaceutical companies, in need of assets to counter flagging sales, are making these so-called antibody-drug conjugates the technology of choice in oncology dealmaking, as illustrated by the recent US$10.1 billion (NZ$16.5b) acquisition of ImmunoGen by AbbVie.If that trend sounds vaguely familiar, you have probably been following the pharma industry for too long. The field has gone through waves of hype and i...

More Bloomberg

How Saudi Arabia turned back climate progress at summit
Politics

How Saudi Arabia turned back climate progress at summit

Oil giant crucial in ensuring nations were not called on to eschew fossil fuels.

Bloomberg 01 Dec 2024
Australia bracing for big wave of retirees
Policy

Australia bracing for big wave of retirees

Around 2.5 million people forecast to start drawing on super in next decade.

Bloomberg 23 Nov 2024
Bird flu threatens home of wandering albatrosses
Bloomberg

Bird flu threatens home of wandering albatrosses

Half of species' 25,000 remaining birds breed on sub-Antarctic island.

Bloomberg 17 Nov 2024
Zuckerberg wants to feed us more AI slop. No, thanks
Technology Opinion

Zuckerberg wants to feed us more AI slop. No, thanks

Meta CEO seeks to flood social feeds with machine-made content.

Bloomberg 09 Nov 2024